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Objective: Aortic reconstructions for primary graft infection (PGI), mycotic aneurysm (MA), and aortic graft-enteric
erosion (AEE) bear high morbidity and mortality rates, and current treatment options are not ideal. Cryopreserved grafts
have been implanted successfully in infected fields and may be suitable for abdominal aortic reconstructions. Registry data
from several institutions were compiled to examine results of cryopreserved aortic allograft (CAA) placement.
Methods: The experience of 31 institutions was reviewed for CAAs inserted from March 4, 1999, to August 23, 2001.
Indications for CAA, organisms, mortality, and complications were identified.
Results: Fifty-six patients, 43 men and 13 women, with a mean age of 66 years (range, 44 to 90 years) had in situ aortic
replacement with CAA. Indications for CAA placement were PGI in 43 patients (77%), MA in seven (14%), AEE in four
(7%), and aortic reconstruction with concomitant bowel resection in two (4%). Infectious organisms were identified in 33
patients (59%); the most frequent organism was Staphylococcus aureus in 17 (52%). Thirty-one patients (55%) needed an
additional cryopreserved segment for reconstruction. The mean follow-up period was 5.3 months (range, 1 to 22
months). One patient died in the operating room, and the 30-day surgical mortality rate was 13% (7/56). Seven
additional patients died during the follow-up period, yielding an overall mortality rate of 25% (14 patients). Two patients
(4%) had graft-related mortality as the result of hemorrhage from the CAA and persistent infection. Graft-related
complications included persistent infection with perianastomotic hemorrhage in five patients (9%), graft limb occlusion
in five (9%), and pseudoaneurysm in one (2%). Three patients (5%) needed amputation.
Conclusion: In situ aortic reconstruction with CAA in infected fields carries a high mortality rate, but most deaths are not
the result of allograft failure. However, CAA infection and lethal hemorrhage caused by graft rupture occurs and is
concerning. Early reinfection was not reported. Late graft-related complications, such as reinfection, thrombosis, or
aneurysmal changes, are unknown. Preliminary data from this registry fail to justify the preferential use of CAA for PGI,
MA, or AEE. A multicenter, randomized study is needed to compare results with established techniques. (J Vasc Surg
2002;35:847-52.)
Despite several options available for the treatment of
aortic graft infection, morbidity and mortality rates remain
high. Extraanatomic bypass with removal of the infected
graft may be associated with limb loss, aortic stump blow-
out, or pelvic ischemia.1-3 In situ antibiotic-soaked polyes-
ter grafts avoid the risk of aortic stump blowout but may
become reinfected, especially when placed in patients with
abscesses.4 Deep lower limb veins have been used in aortic
reconstruction but necessitate prolonged operative time
and may have resultant venous morbidity.5 Success of cryo-
preserved tissue has been reported in the chest for replace-
ment of infected aortic valves or mycotic thoracic aneu-
rysms. Potential advantages of aortic graft replacement with
cryopreserved allografts include easy availability, avoidance
of deep vein excision, ability to maintain pelvic blood flow
with in situ replacement, and theoretically reduced reinfec-
tion rates. Potential allograft complications include poor
graft integrity resulting in rupture or aneurysm, reinfection,
or thrombosis. Series of patients with abdominal cryopre-
served aortic allograft (CAA) placement have been reported
in Europe with good early success rates.6-8 Because of the
small number of patients identified with abdominal aortic
graft infections or mycotic aneurysms (MAs), a national
registry of patients who underwent CAA implant proce-
dures was developed.
METHODS
The United States Cryopreserved Aortic Allograft Reg-
istry was established to collect clinical data on patients who
underwent placement of a CAA in the United States after
March 4, 1999. Indications for CAA placement included
primary graft infection (PGI) placed for abdominal aortic
aneurysm or occlusive disease, MA, aortoenteric erosion/
fistula (AEE), or aortic reconstruction with concomitant
bowel resection. The data were collected on data sheets for
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each patient and were entered in a computerized database.
Only abdominal aortic reconstructions were included; tho-
racic CAAs and infrainguinal cryopreserved grafts were not
subjects of this study. All cryografts (CryoLife, Inc, Kenne-
saw, Ga) were stored at180°C to196°C and thawed at
37°C to 42°C. Clinical history, indications for CAA place-
ment, type of organisms identified, type of CAA implanted,
surgical and overall mortality, major and minor complica-
tions, including graft-related complications, were reported.
The registry is located at the Mayo Clinic and funded with
internal funds. Data submission was voluntary, but all
surgeons placing CAAs were requested to submit patient
data if possible and had the option of submitting data
anonymously. Twenty institutions submitted data on one
patient each, five submitted two patients each, three sub-
mitted three patients each, three submitted four patients
each, and one submitted five patients.
RESULTS
Thirty-one institutions submitted data for 56 patients,
43 men and 13 women, who underwent abdominal aortic
reconstruction with cryopreserved allograft between March
4, 1999, and August 23, 2001. Mean patient age was 66
years (range, 44 to 90 years). Twenty-two patients (39%)
had hypertension, 19 (34%) had peripheral vascular disease,
17 (30%) had coronary artery disease, 13 (23%) had chronic
obstructive pulmonary disease, and five (9%) had diabetes.
Twenty-nine patients (52%) had received intravenous anti-
biotics before operation. Forty-three patients (77%) had
PGI, including two patients with paraanastomotic
pseudoaneurysms. Seven (14%) had MAs, including one
patient with a ruptured aneurysm and one with an adjacent
lumbar disk space infection. Other indications included
AEE in four patients (7%) and elective aortic reconstruction
with concomitant bowel resection in two (4%), one with
resection of small bowel and a mesenteric sarcoma and one
with left colon resection. One patient with a MA was
infected with human immunodeficiency virus. Clinical or
radiographic evidence of infection was present in all pa-
tients, although infectious organisms were identified in
blood cultures or intraoperative cultures in 33 patients
(59%). Organisms included Staphylococcus aureus in 17
patients (52%), Streptococcus in six (11%), Staphylococcus
epidermidis in five (9%), Pseudomonas, Enterococcus, and
Escherichia coli in three (5%) each, mixed anaerobic bacteria
in two (4%), and Mycobacterium and Candida albicans in
one each. Eight patients had multiple organisms present.
Five procedures (9%) were urgent or emergency oper-
ations performed within 24 hours of initial presentation,
including one patient with a ruptured MA. Thirty-one
patients (55%) needed an additional cryopreserved segment
for reconstruction. One patient had a segment of cryopre-
served descending thoracic aorta to extend the proximal
aorta reconstruction in the juxtarenal portion. The remain-
ing 30 patients had distal extensions of the CAA with
cryopreserved superficial femoral artery (n  23; 41%; Fig
1), cryopreserved superficial femoral vein (n  5; 9%), and
cryopreserved iliac artery (n  2; 4%). Two additional
patients had graft extension with prosthetic graft (n  1)
and autogenous superficial femoral artery (n  1).
The mean follow-up period was 5.3 months (range, 0
to 22 months), with a median follow-up period of 2
months. One patient died in the operating room as the
result of disruption of the aorta to graft anastomosis. The
30-day surgical mortality rate was 13% (7/56), and the
in-hospital mortality rate was 18% (10/56). Four addi-
tional patients died during the follow-up period, yielding
an overall mortality rate of 25% (14 patients). Two patients
(4%) had graft-related mortality as the result of hemorrhage
from the CAA and persistent infection. Other causes of
death were sepsis or multisystem organ failure in five pa-
tients (9%), unknown in three (5%), endocarditis, gastroin-
testinal hemorrhage, myocardial infarction, and complica-
tions of renal failure in one patient each. Three of five
patients who underwent repair with an emergency opera-
tion died in the first 30 postoperative days, and two of these
patients had graft-related mortality. Of the eight patients
with multiple organisms cultured, three died, but no graft-
related deaths occurred and only one death occurred within
30 days of operation. Two of four patients (50%) with AEE
died, compared with 12 of the 51 patients (24%) with other
causes of infection.
After operation, 28 of 55 patients (51%) had one or
more complications. Fourteen were graft-related complica-
tions and included persistent infection with perianasto-
motic hemorrhage in five patients (9%), graft limb occlu-
sion in five (9%), and pseudoaneurysm in one (2%). Of the
five patients with persistent infection and perianastomotic
hemorrhage, two died and one needed explantation. Three
of the five patients with perianastomotic hemorrhage had
multiple organisms with culture. The graft-related morbid-
ity rate in the urgent/emergency group was 40% (two of
five patients) and in the elective group was 24% (12 of 50
patients). Three patients (5%) needed amputation. One
graft was explanted for reinfection, and an axillofemoral
bypass was placed. A second patient needed explant of one
Fig 1. Preparation of aortobifemoral CAA with addition of cryo-
preserved superficial femoral artery graft. Cryopreserved superficial
femoral artery was divided in half, and each segment was anasto-
mosed to iliac limbs of aortoiliac cryopreserved graft.
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femoral limb. No reinfection occurred at 1 month after
operation. Complications are listed in Table I. Primary
follow-up graft assessment was documented with com-
puted tomography in 20 patients (36%; Fig 2), ultrasound
scan in five (9%), indium-labeled white blood cell scan in
four (7%), magnetic resonance imaging in one (2%), and
physical examination alone in 25 (45%). Four patients (7%)
had multiple methods of graft surveillance. At time of last
follow-up, of the 42 surviving patients, 93% had a patent
graft, 95% were infection-free, and 93% had limb salvage.
DISCUSSION
Because of the high mortality and morbidity rates (20%
to 50%) associated with replacement of the aorta in infected
fields, several treatment options have been used in the past
20 years.1-3 The most common options include resection of
the infected graft with oversewing of the aortic stump and
extraanatomic bypass, in situ placement of an antibiotic-
soaked graft, deep venous reconstruction, or cryopreserved
graft. Ex situ retroperitoneal aortic bypass9 and nonresec-
tional strategies, such as antibiotic irrigation,10 are less
commonly used.
The most traditional intervention for aortic graft infec-
tion is placement of extraanatomic bypass with resection of
the graft.11,12 Complications of this approach are aortic
stump blowout, which is often fatal, axillofemoral graft
thrombosis or infection, or amputation. Yeager et al11
reported 60 patients treated with this approach, resulting in
a perioperative mortality rate of 13% and a 5-year primary
axillofemoral graft patency rate of 73% (Table II). No
reported cases of aortic stump blowout were found. In this
approach, graft patency remains a concern, especially in
younger patients with an extraanatomic bypass. Darling et
al9 suggested a modification of this approach with tunnel-
ing a retroperitoneal in-line aortic bypass through nonin-
fected tissue planes. In 16 patients, 30-day mortality rate
was 0% and limb salvage rate was 100%. With a mean
follow-up period of 32 months, no reinfection was noted.
Although this technique may be a reasonable option, larger
series with longer follow-up periods will be needed.
Several authors favor in situ graft replacement with
antibiotic-soaked graft. In a previous report from the Mayo
Clinic of 52 patients with aortoenteric fistula, 10 had in situ
aortic replacement with a 50% 30-day surgical mortality
rate after emergency repair and 17% after elective repair.13
Complications included one amputation, but none of the
seven survivors had evidence of infection at recent evalua-
tion. In our more recent experience, 25 patients, treated at
our institution for aortic graft infection of any cause, had
8% mortality and a 100% limb salvage rates4 (Table II). In
this series, a trend of decreased reinfection was evident with
rifampin-soaked grafts and in patients with aortoenteric
fistulae. This series emphasized the importance of graft
coverage with autogenous tissue because a 360-degree
omental wrap conferred significant protection from reinfec-
tion. The Leicester group found a poor prognosis in pa-
tients treated with in situ graft replacement with methicil-
lin-resistant S aureus.14
Autologous reconstruction offers the best option for
prevention of recurrent infection but may necessitate a
tedious, complex operation. In situ aortic grafting with












Renal failure 2 (4%)
Respiratory failure 2 (4%)
Sepsis 2 (4%)
Femoral lymphocele 2 (4%)
Mesenteric ischemia 1 (2%)
Paralysis 1 (2%)
Stroke 1 (2%)
Ventral hernia 1 (2%)
Gastrointestinal hemorrhage 1 (2%)
Prolonged ileus 1 (2%)
Wound infection 1 (2%)
Fig 2. Three-dimensional reconstruction computed tomo-
graphic scan of postoperative aortoiliac cryopreserved graft. Axial
images showed good incorporation of graft to surrounding tissue.
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 5 Noel et al 849
superficial femoral-popliteal veins has been proposed by
Clagett, Valentine, and Hagino.5 In their series of 41
patients, they reported a 7.3% 30-day surgical mortality rate
and a 49% complication rate, including a 5% amputation
rate (Table II). Four patients had long-term moderate
venous morbidity. No reinfection was noted. Duration of
the operation was 7 to 8 hours. Autologous reconstruction
often necessitates a specialized two-team approach to expe-
dite the operation and may be difficult in sick patients who
need urgent treatment.
Because of the often disappointing results and complex
morbidity associated with the previous options, CAAs have
been used recently with increasing frequency. Good results
with cryopreserved valve homografts are known,15,16 and
replacement for thoracic MAs has been encouraging.17
CAAs are easily available but are expensive. Experience with
in situ replacement of cryopreserved allograft for infected
abdominal fields still is limited. Initial studies by Koskas et
al,18 reporting storage of fresh allografts at 4°C, resulted in
an 18% mortality rate in a series of 83 patients. Four
patients (5%) had late dilation of the allograft segment and
15 patients (18%) had late occlusive lesions.
Evolving techniques of cryopreservation, including
storage at 180°C to 196°C, may reduce antigenicity
and improve the cellular integrity of the allograft, thus
decreasing graft-related morbidity. Vogt et al19 reported
weak T cell–mediated rejection to adult arterial allografts.
Carpenter and Tomaszewski20 defined the immunogenic
response in cryopreserved venous allografts to be T-cell
mediated, suggesting the control of this response could
improve local graft patency or stability. The need for im-
munosuppression has not been addressed in the literature
and will need to be resolved in the future.
Data are conflicting regarding the incidence of graft
rupture, aneurysm, and stenosis. Reports from both Vogt
et al21,22 and Chiesa et al7 support the use of CAAs, with a
30-day surgical mortality rate from 6% to 13% and an
allograft related death rate of 5% to 9%, without evidence of
suture line rupture, aneurysm, or stenosis, at a mean fol-
low-up period of 18 months. Similar results were noted by
Leseche et al,8 who reviewed 28 patients with a mortality
rate of 17%, no amputation, three patients with aneurysmal
degeneration, and one with stenosis. Similar to these Eu-
ropean series, our 30-day mortality rate was 13%, and the
allograft-related mortality rate was 4%. The overall mortal-
ity rate of 30% likely reflects the complex, multisystem
dysfunction of these patients. The European Homograft
Bank data included early and late graft-related mortality
rates of 5% and 3% in a group of 90 patients.23
However, da Gama et al24 described histologic degen-
eration of the media in cryopreserved grafts, leading to
secondary aneurysmal or thrombotic changes. Lehalle et
al25 reported three cases of early allograft rupture from
minutes to hours after operation and two cases of early,
severe dilation. In our series, we observed five patients with
perianastomotic hemorrhage and rupture, including one
occurring at the time of operation, whereas five had graft
limb occlusion, and one had pseudoaneurysm. Whether
very early graft rupture is related to rejection or cryopreser-
vation techniques is unclear. Because of these histologic
changes, cryopreserved grafts may not be long-term solu-
tions but may be considered as a bridge to allow resolution
of infection before in situ prosthetic graft replacement.
Another limitation of CAA is the need for additional seg-
ments of allografts to lengthen the graft. Extensions were
necessary in more than half of our patients and add to
operative time.
Questions regarding resistance to infection remain.
Experimental animal studies suggest that cryopreserved
grafts may be more resistant to reinfection. Knosella et al26
and Camiade et al27 each reported bacterial resistance of
cryopreserved allografts after antibiotic treatment. How-
ever, Rowe et al28 showed that collagen-impregnated Da-
cron grafts were equivalent or superior to CAAs at resisting
infection in pig ascending aorta. In this series, no early
reinfection was reported. However, long-term reinfection
can occur clinically and, when it does, may present as
pseudoaneurysm or hemorrhage. Indications for life-long
antibiotic treatment are not well documented, but all pa-
tients at our institution remain on suppressive antibiotics.
An additional clinical indication for CAA may be elec-
tive concomitant bowel resection. The two patients in our
series treated with that indication did well without compli-
cations. Vogt et al6 reported similar good results. That









stump; Yeager, 199911 (N  60)
13%; 33% (2 year),
53% (5 year)
6 (10%) 2 (3%) 7 (12%) 6 (10%)
Prosthetic in situ aortic graft
replacement; Young 19994 (N  25)
8%; 24% 0 (0) 1 (4%) 1 (4%) 5 (22%)
Deep venous in situ replacement;
Clagett, 19975 (N  4)
7%; 24% 2 (5%) 0 (0) 3 (7%) 0 (0)
Cryopreserved aortic allograft; present
study, 2001 (N  56)
13%; 30% 3 (5%) 5 (9%) 5 (9%) 0 (0)
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most authors recommend omentoplasty for CAA coverage
in all situations, but especially in those with abscess, is
important to note.
CAAs are a potential, feasible alternative for replace-
ment of infected aortic grafts. Early results from the United
States Cryopreserved Aortic Allograft are similar to previ-
ous reports, with high morbidity but relatively low graft-
related mortality rates. Although the limitations of a regis-
try format with voluntary enrollment may underestimate
mortality or complication rates, early data suggested resis-
tance of CAA to reinfection. Concerns of graft rupture,
aneurysm, stenosis, late reinfection, and rejection remain.
Further data acquisition, preferably with a multicenter,
randomized study, will be necessary to compare this prom-
ising technique with established treatment options.
We thank Marcia Simonson for manuscript preparation
and Leanne Barry for data management.
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MD, St Louis University Medical Center, St Louis, Mo;
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Gregory S. Keagy, MD, Harrisburg Hospital, Harrisburg,
Pa; Alan B. Lumsden, MD, Baylor University, Houston,
Tex; Venkat R. Machiraju, MD, Shadyside Hospital, Pitts-
burgh, Pa; Navid Forozan, MD, Shadyside Hospital, Pitts-
burgh, Pa; Douglas S. Paget, MD, Methodist Hospital,
Indianapolis, Ind; Michael A. Palmer, MD, General Hos-
pital of Eureka, Eureka, Calif; Gary J. Peterson, MD, St
Louis University Medical Center, St Louis, Mo; William C.
Pevec, MD, University of California-Davis, Sacramento,
Calif; William J. Quinones-Baldrich, MD, University of
California-Los Angeles, Los Angeles, Calif; Richard
Razzino, MD, Harrisburg Hospital, Camp Hill, Pa; Hazim
Safi, MD, University of Texas, Houston, Tex; Christian D.
Schunn, MD, West Virginia University, WVa; Lewis B.
Schwartz, MD, University of Chicago, Chicago, Ill; Wil-
liam S. Stevens, MD, St John’s Hospital, Mo; Brad M.
Sweda, MD, Prairie Thoracic and Cardiovascular Surgeons,
Springfield, Ill; Ronald Webb, MD, Summit Medical Cen-
ter, Walnut Creek, Calif; Walter M. Whitehouse, Jr, MD,
Michigan Heart and Vascular Institute, Ypsilanti, Mich; G.
Mel Williams, MD, Johns Hopkins University, Baltimore,
Md; Catherine Wittgen, MD, St Louis University Medical
Center, St Louis, Mo; Seth W. Wolk, MD, St Joseph’s
Mercy Hospital, Ann Arbor, Mich.
DISCUSSION
Dr Timothy Baxter (Omaha, Neb). One of the questions is
about this graft falling apart during the surgery. The first thing that
occurred to me is a problem with the way the graft was preserved.
Do you have any way to know when you put the graft in if there is
a problem with the preservation that may lead to this type of a
problem?
Dr Audra Noel. I can only speak from our experience with a
few patients. It seems that the grafts are relatively easy to manage,
but we did receive some aortoiliac segments that were thin-walled
near the iliac bifurcation. These segments were concerning, so we
actually excised those portions before we added the femoral limbs.
It is not really clear because these are multicenter data. Those
surgeons who had problems just in the operating room, I would
think that would be an issue of cryopreservation technique. For a
few days later or weeks later, it is difficult to say whether the graft
breakdown was persistent infection in the wall of the aorta. We do
not have those cultures or that exact information, and not being
there, it is hard to say what that remaining aorta looked like. That
would be difficult to say, but I would agree that in the operating
room if you have problems it is probably the quality of that
cryopreserved tissue.
Dr Alexander Shepard (Detroit, Mich). I also enjoyed your
presentation a great deal. I wonder if you have any information on
the difference in outcome between the gram-positive infections
and the few patients you had with gram-negative infections and in
particular if perhaps your late infection patients and your paraanas-
tomotic hemorrhage patients were predominantly gram-negative
infections at the time of their initial procedure.
Dr Noel. Actually, the numbers are a little too small to
compare, but there was not a big difference between the gram-
positive and gram-negatives. Typically the groups that were gram-
negatives that had aortic enteric erosions did better, but they
typically do better. Since most of them had S aureus, the type of
infectious organism did not seem to affect outcome one way or the
other.
In “Treatment of type 2 endoleaks after endovascular repair of abdominal aortic aneurysms: Comparison of
transarterial and translumbar techniques” (Baum RA, Carpenter JP, Golden MA, Velazquez OC, Clark TWI,
Stavropoulos SW, Cope C, Fairman RM. J Vasc Surg 2002;35:23-9).
There is an error in the author list. The sixth author’s name is incorrectly given as S. William Stavropoulous. His last
name, correctly spelled, is Stavropoulos.
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